ADS051


Associated tags: Neutrophil, Safety, FPR1, Ulcer, MRP2, Patient, Inflammation, Ulcerative colitis, Pharmaceutical industry, Trial of the century, Therapy, Inflammatory bowel disease, IBD, UC, Medicine

Locations: COLON

Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, General Health, Health, Genetics, Clinical Trials, Patient, Multimedia, Inflammation, Medicine, Ulcerative colitis, IBD, Trial of the century, RNA, Inflammatory bowel disease, Pharmaceutical industry, Medical imaging

Geneoscopy, Inc., a life sciences company focused on developing noninvasive diagnostic and precision medicine tools for gastrointestinal health, and Adiso Therapeutics, Inc., a clinical-stage biotechnology company advancing novel medicines to treat inflammatory diseases, today announced a strategic collaboration to further treatment options available for patients with inflammatory bowel disease (IBD).

Key Points: 
  • Geneoscopy, Inc., a life sciences company focused on developing noninvasive diagnostic and precision medicine tools for gastrointestinal health, and Adiso Therapeutics, Inc., a clinical-stage biotechnology company advancing novel medicines to treat inflammatory diseases, today announced a strategic collaboration to further treatment options available for patients with inflammatory bowel disease (IBD).
  • View the full release here: https://www.businesswire.com/news/home/20231205408799/en/
    “Utilizing our RNA biomarker platform to assess stool samples from IBD patients and categorize response to treatment with ADS051 is an exciting opportunity,” said Andrew Barnell, CEO of Geneoscopy.
  • This collaboration comes at a critical time for the estimated 3 million Americans living with IBD .
  • The Adiso ADS051 Phase 2 clinical study will be conducted globally and begin recruiting in 2024.

Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis

Retrieved on: 
Sunday, October 22, 2023
Molecule, FDA, Trial of the century, American College, Harvard Medical School, Crohn's disease, UC, ACG, Naval Hospital Boston, Inflammation, Pathology, Safety, MAD, American College of Gastroenterology, SAD, Ulcerative colitis, Clinical trial, FPR1, MRP2, Therapy, Associate, Pharmaceutical industry, Patient, Medicine

CONCORD, Mass., Oct. 22, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced positive topline data from its Phase 1b multiple ascending dose (MAD) clinical trial evaluating ADS051 (BT051) in patients with moderate-to-severe ulcerative colitis (UC). The data were presented today at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting being held October 20-25, in Vancouver, Canada.

Key Points: 
  • ADS051 is a first-in-class, oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation via inhibition of MRP2 and FPR1.
  • The randomized, double-blind, placebo-controlled, MAD Phase 1b study enrolled 24 moderately-to-severely active UC patients, all of whom completed the trial as planned over the 28-day treatment period ( NCT05084261 ).
  • "ADS051 efficacy measures reveal encouraging signals of pharmacologic activity and clinical benefit versus placebo, after 28 days of treatment.
  • Given these findings and a recently completed positive end-of-Phase 1 FDA interaction, we plan to advance ADS051 in a Phase 2 clinical study in early 2024."

Adiso Therapeutics Expands Board of Directors with Appointment of Robert Lisicki

Retrieved on: 
Thursday, October 12, 2023
Acquisition, UC, Amgen, Regeneron Pharmaceuticals, Inflammation, Trial of the century, IBD, Strategic planning, State university system, BS, Inflammatory bowel disease, Arena Pharmaceuticals, Transgene (company), Ulcerative colitis, Therapy, Immunology, JNJ, Janssen Pharmaceuticals, State University of New York Upstate Medical University, Economics, Pfizer, MRP2, Patient, Neutrophil, Pharmaceutical industry, Circulatory system, Pain

CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.

Key Points: 
  • CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.
  • "The Adiso Board and I are very pleased to welcome Robert Lisicki.
  • Rob is an accomplished biopharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition," said Jason Dinges, Morningside Technology Advisory and Adiso Board Member.
  • Mr. Lisicki has nearly 30 years of experience in the pharma/biotech sector, most recently serving as Chief Executive Office and Board Member of InCarda Therapeutics.